FDA to Speed Up Review of Krazati Combo for Metastatic CRC

The Food and Drug Administration granted a priority review to Krazati plus Erbitux for KRAS G12C-mutant locally advanced or metastatic colorectal cancer.

Related Keywords

Anne Kerber ,Krazati Erbitux ,Bristol Myers Squibb ,Drug Administration ,National Comprehensive Cancer Network ,Cell Therapy ,New England Journal ,Pancreatic Cancer ,Clinical Oncology ,News ,Colorectal Cancer ,Fda ,Priority Review ,Krazati ,